When and how can endpoints be changed after initiation of a randomized clinical trial?

PLoS Clinical Trials

Volumn 2, Issue 4, 2007, Pages

  Evans, Scott ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; CLINICAL RESEARCH; EVIDENCE BASED MEDICINE; MEDICAL DOCUMENTATION; METHODOLOGY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT CARE; STATISTICAL ANALYSIS;

EID: 34249805427     PISSN: None     EISSN: 15555887     Source Type: Journal    
DOI: 10.1371/journal.pctr.0020018     Document Type: Article

References (12)

1. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1998) ICH harmonized tripartite guideline: Statistical principles for clinical trials, E-9. Available: http://www.ich.org/LOB/media/MEDIA485.pdf. Accessed 6 March 2007.
2. Dormandy J, Charbonnel B, Eckland D, Erdmann E, Massi-Benedetti M, et al. (2006) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomized controlled trial. Lancet 366: 1279-1289.
3. Skyler JS (2005) PROactive results overstated and misleading. DOC News 2: 4.
4. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A (2004) The prospective pioglitazone clinical trial in macrovascular events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 27: 1647-1653.
5. Dormandy J, Charbonnel B, Eckland D, Erdmann E, Massi-Benedetti M, et al. (2006) PROactive study. Lancet 367: 982.
6. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG (2004) Empirical evidence for selective reporting of outcomes in randomized trials. JAMA 291: 2457-2465.
7. Chan AW, Krleza-Jeric K, Schmid I, Altman DG (2004) Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. Can Med Assoc J 171: 735-740.
8. Wittes J (2002) On changing a long-term trial midstream. Stat Med 27: 2789-2795.
9. [No authors listed] (1997) The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. The Post Artery Bypass Graft Trial Investigators. N Engl J Med 336: 153-162.
10. Young F, Nightingale S, Temple R (1988) The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction. JAMA 259: 3158-3160.
11. Cairns J, Cohen L, Colton T, DeMets D, Deykin D, et al. (1991) Issues in the early termination of the aspirin component of the Physicians' Health Study. Data Monitoring Board of the Physicians' Health Study. Ann Epidemiol 1: 395-405.
12. Hawkey CJ (2001) Journals should see original protocols for clinical trials. BMJ 323: 1309.